You are here

Article Text

Article menu
Download PDFPDF
Matters arising
Etanercept treatment of rheumatoid arthritis in the “real world”
  1. M D Smith1
  1. 1Rheumatology Research Unit, Repatriation General Hospital, Daws Road, Daw Park South Australia 5041
  1. Correspondence to:
    Professor M D Smith;
    malcolm.smith{at}rgh.sa.gov.au

https://doi.org/10.1136/ard.62.1.95

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A recent paper in the Annals of the Rheumatic Diseases attempted to examine the “real world” experience of etanercept treatment by examining the incidence of flares of rheumatoid arthritis (RA) disease activity in a cohort of patients with RA who had started treatment with etanercept before September 1999.1 The number of flares and patients experiencing flares within the first year of etanercept treatment was compared with that seen in the same cohort of patients the year before they started etanercept. It is well documented that the withdrawal rate from disease modifying antirheumatic drug (DMARD) treatment in RA increases with the length of time the patient has been receiving the drug and that a number of these withdrawals relate to loss of efficacy.2–4 Therefore, it is reasonable to assume that the number of disease …

    View Full Text